Continuous subcutaneous insulin infusion or insulin pump therapy (IPT) can improve glycaemic management and the quality of life of people living with type 1 diabetes (T1D) compared with multiple daily injections (MDI) [1–3]. The gene discussed is INS; the disease is type 1 diabetes mellitus.